Discovery of tetrahydroisoquinoline-based CXCR4 antagonists

ACS Medicinal Chemistry Letters

Volumn 4, Issue 11, 2013, Pages 1025-1030

  Truax, Valarie M ^a   Zhao, Huanyu ^a   Katzman, Brooke M ^a   Prosser, Anthony R ^a   Alcaraz, Ana A ^a   Saindane, Manohar T ^a   Howard, Randy B ^a   Culver, Deborah ^a   Arrendale, Richard F ^a   Gruddanti, Prahbakar R ^a   Evers, Taylor J ^a   Natchus, Michael G ^a   Snyder, James P ^a   Liotta, Dennis C ^a   Wilson, Lawrence J ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

CXCR4 antagonists; CXCR4 receptor; HIV; Tetrahydroisoquinolines; WBC mobilization

Indexed keywords

CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; TETRAHYDROISOQUINOLINE;

ARTICLE; CALCIUM TRANSPORT; DRUG BIOAVAILABILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; MOBILIZATION; NONHUMAN; PRIORITY JOURNAL; STEREOISOMERISM;

EID: 84887981738     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400183q     Document Type: Article

References (29)

1. Peled, A.; Wald, O.; Burger, J. Development of novel CXCR4-based therapeutics Expert Opin. Invest. Drugs 2012, 21, 341-353
2. Lapidot, T.; Petit, I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells Exp. Hematol. 2002, 30, 973-981
3. Tzeng, Y.; Li, H.; Kang, Y. L.; Chen, W. C.; Chen, W. C.; Lai, D. M. Loss of CXCL12/SDF-1 in adult mice decreases the quiescent state of hematopoietic stem/progenitor cells and alters the pattern on hematopoietic regeneration after myelosuppresion Blood 2011, 117, 429-439
4. Tachibana, K.; Hirota, S.; Iizasa, H.; Yoshia, H.; Kawabata, K.; Kataoka, Y.; Kitamura, Y.; Matsushima, K.; Yoshida, N.; Nishikawa, S.; Kishimoto, T.; Nagasawa, T. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract Nature 1998, 393, 591-594
5. Zou, Y.; Kottman, A. H.; Kuroda, M.; Taniuchi, I.; Littman, D. R. The function of the chemokine receptor CXCR4 in hematopoiesis and in cellular development Nature 1998, 393, 595-599
6. Nagasawa, T.; Tachibana, K.; Kawabata, K. A CXC chemokine SDF-1/PBSF: a ligand for a HIV co-receptor, CXCR4 Adv. Immunol. 1999, 71, 211-228
7. De Clercq, E. The bicyclam AMD3100 story Nat. Rev. Drug Discovery 2003, 2, 581-587
8. Oberlin, E.; Amara, A.; Bachelerie, F.; Bessia, C.; Virelizier, J. L.; Arenzana-Seisdedos, F.; Schwartz, O.; Heard, J. M.; Clark-Lewis, I.; Legler, D. F.; Loetscher, M.; Baggiollni, M.; Moser, B. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 Nature 1996, 382, 833-935
9. Dipersio, J. F.; Yasothan, U.; Kirkpatrick, D. Plerixafor Nat. Rev. Drug Discovery 2009, 8, 105-106
10. Balkwell, F. Cancer and the chemokine network Nat. Rev. Cancer 2004, 4, 540-550
11. Zlotnik, A. New Insights on the role of CXCR4 in cancer metastasis J. Pathol. 2008, 215, 211-213
12. Teicher, B. A.; Fricker, S. P. CXCL12(SDF-1)/CXCR4 pathway in cancer Clin. Cancer Res. 2010, 16, 2927-2931
13. Burger, J. A.; Peled, A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers Leukemia 2009, 23, 43-52
14. Wilson, L. J.; Liotta, D. C. Emergence of small-molecule CXCR4 antagonists as novel immune and hematopoietic system regulatory agents Drug Dev. Res. 2011, 72, 598-602
15. Choi, W.-T.; Duggineni, S.; Xu, Y.; Huang, Z.; An, J. Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4) J. Med. Chem. 2012, 55, 977-994
16. Skerlj, R. T.; Bridger, G. J.; Kaller, A.; McEachem, E. J.; Crawford, J. B.; Zhou, Y.; Atsma, B.; Langille, J.; Nan, S.; Veale, D.; Wilson, T.; Harwig, C.; Hatse, S.; Princen, K.; DeClercq, E.; Schols, D. Discovery of a novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication J. Med. Chem. 2010, 53, 3376-3388
17. Stone, N. D.; Dunaway, S. B.; Flexner, C.; Tierney, C.; Calandra, G. B.; Becker, S.; Cao, Y.-J.; Wiggins, I. P.; Conley, J.; MacFarland, R. T.; Park, J.-G.; Lalama, C.; Snyder, S.; Kallungal, B.; Klingman, K. L.; Hendrix, C. W. Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects Antimicrob. Agents Chemother. 2007, 51 (7) 2351-2358
18. Jenkinson, S.; Thomson, M.; McCoy, D.; Edelstein, M.; Danehower, S.; Lawrence, W.; Wheelan, P.; Spaltenstein, A.; Gudmundsson, K. Blockade of X4-tropic HIV-1 cellular entry by GSK812397, a potent noncompetitive CXCR4 receptor antagonist Antimicrob. Agents Chemother. 2010, 54 (2) 817-824
19. Thoma, G.; Streiff, M. B.; Kovarik, J.; Glickman, F.; Wagner, T.; Beerli, C.; Zerwes, H.-G. Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo J. Med. Chem. 2008, 51, 7915-7920
20. Nyunt, M.; Becker, S.; MacFarland, R. T.; Chee, P.; Scarborough, R.; Everts, S.; Calandra, G. B.; Hendrix, C. W. Pharmacokinetic effect of AMD070, an oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromorphan in healthy volunteers J. Acquired Immune Defic. Syndr. 2008, 47, 559-565
21. Cao, Y. J.; Flexner, C. W.; Dunaway, S.; Park, J. G.; Klingman, K.; Wiggins, I.; Conley, J.; Radebaugh, C.; Kashuba, A. D.; MacFarland, R.T.; Becker, S.; Hendrix, C. W. Effect of low-dose ritonavir on the pharmakokinetics of the CXCR4 antagonist AMD070 in healthy volunteers Antimicrob. Agents Chemother. 2008, 52 (5) 1630-1634
22. Kettle, J. G.; Ward, R. A.; Griffen, E. Data-mining patent literature for novel chemical reagents for use in medicinal chemistry design Med. Chem. Commun. 2010, 1, 331-338
23. Thomas, J. B.; Atkinson, R. N.; Rothman, R. B.; Fix, S. E.; Mascarella, S. W.; Vinson, N. A.; Xu, H.; Dersch, C. M.; Lu, Y.-F.; Cantrell, B. E.; Zimmerman, D. M.; Carroll, F. I. Identification of the first trans-(3 R,4 R)-dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid κ receptor antagonism activity J. Med. Chem. 2001, 44, 2687-2690
24. Lackman-Smith, C.; Osterling, C.; Luckenbaugh, K.; Mankowski, M.; Snyder, B.; Lewis, G.; Paull, J.; Profy, A.; Ptak, R. G.; Buckheit, R. W.; Watson, K. M.; Cummins, J. E.; Sanders-Beer, B. E. Development of a comprehensive human immunodeficiency virus type I screening algorithm for discovery and preclinical testing of topical microbicides Antimicrob. Agents Chemother. 2008, 52 (5) 1768-1781
25. Miller, J. F.; Gudmundson, K. S.; D'Aurora Richardson, L.; Jenkinson, S.; Spaltenstein, A.; Thomson, M.; Wheelan, P. Synthesis and SAR of novel isoquinoline CXCR4 antagonists with potent anti-HIV activity Bioorg. Med. Chem. Lett. 2010, 20, 3026-3030
26. Wong, R.; Bodart, V.; Metz, M.; Labrecque, J.; Bridger, G.; Fricker, S. Comparison of the multiple binding modes of bicyclam, monocyclam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors Mol. Pharmacol. 2008, 74, 1485-1495
27. Wu, B.; Chein, E. Y.; Mol, C. D.; Fenalti, G.; Liu, W.; Katritch, V.; Abagyan, R.; Brooun, A.; Wells, P.; Bi, F. C.; Hamel, D. J.; Kuhn, P.; Handel, T. M.; Cherezov, V.; Stevens, R. C. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists Science 2010, 330, 1066-1071
28. Brelot, A.; Heveker, N.; Montes, M.; Alizon, M. Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities J. Biol. Chem. 2000, 275, 23736-23744
29. Lack, N. A.; Green, B.; Dale, D. C.; Calandra, G. B.; Lee, H.; MacFarland, R. T.; Badel, K.; Liles, W. C.; Bridger, G. A pharmacokinetic- pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100 Clin. Pharmacol. Ther. 2005, 77, 427-436